Literature DB >> 8874264

Diagnosis and treatment of ventilator-associated pneumonia--impact on survival. A decision analysis.

T R Sterling1, E J Ho, W T Brehm, M B Kirkpatrick.   

Abstract

STUDY
OBJECTIVE: To determine the impact of antibiotic treatment of ventilator-associated pneumonia (VAP) on survival.
DESIGN: Decision analysis. PATIENTS: A hypothetical cohort of immunocompetent patients receiving mechanical ventilation who have suspected bacterial pneumonia. The analysis was performed separately for the following diagnostic techniques: clinical criteria, bronchoscopic protected specimen brush (PSB), and nonbronchoscopic protected BAL (pBAL). Additional factors accounted for in the analysis included the presence or absence of prior antibiotic use, mortality of antibiotic-treated and untreated pneumonia, mortality attributable to VAP, development of antibiotic resistance, and mortality due to adverse drug reactions. MEASUREMENTS AND
RESULTS: The overall survival of patients who receive antibiotic therapy was compared to survival if antibiotic therapy had been withheld. Antibiotic treatment of clinically diagnosed VAP was associated with lower overall survival than withholding treatment. Antibiotic treatment of VAP diagnosed by invasive (PSB) or semi-invasive (pBAL) techniques was associated with better survival than withholding treatment, although withholding antibiotic therapy was favored as the mortality rate of antibiotic-treated VAP approached 70%.
CONCLUSIONS: Invasive or semi-invasive diagnostic techniques should be used to diagnose VAP, guide therapy, and thereby potentially improve survival. A prospective, randomized trial assessing outcome according to diagnostic technique is needed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874264     DOI: 10.1378/chest.110.4.1025

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 2.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Brad Spellberg; George Talbot
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

4.  Agreement of decision analyses and subsequent clinical studies in infectious diseases.

Authors:  Joshua N Bress; Todd Hulgan; Jennifer A Lyon; Cecilia P Johnston; Harold Lehmann; Timothy R Sterling
Journal:  Am J Med       Date:  2007-05       Impact factor: 4.965

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.